908 Devices Inc. (MASS): M&A transaction — 908 Devices sells desktop bioprocessing PAT portfolio to Repligen for $70M cash

908 Devices Inc.

Purchase price $70M in cash, subject to customary working capital adjustment and escrow for indemnification.
Products sold: MAVERICK, MAVEN, REBEL, ZipChip; 908 Devices retains handheld device business.
Company agrees to 5-year non-compete in bioprocessing PAT and 18-month employee non-solicit.
Transition services provided through Dec 2025; supply and IP license agreements also executed.
Disposition does not require stockholder approval as it is not substantially all assets; pro forma financials to follow.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

908 Devices Inc. completed a disposition involving Repligen Corporation and Repligen GmbH for $70,000,000 (closed 2025-03-04).

Action: disposition
Counterparty: Repligen Corporation and Repligen GmbH
Consideration: $70,000,000
Closing: 2025-03-04

Exact text from the filing

US Purchaser and the German Purchaser. The purchase price payable by the Purchasers for the Transferred Equity Interests and Purchased Assets under the Purchase Agreement was $70,000,000, subject to customary adjustment for working capital as more fully set forth in the Purchase Agreement. A portion of the purchase price will be held in escrow for a period of time

View on SEC.gov

31 m&a transactions filed in the last 30 days. Browse all m&a transactions →

908 Devices Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-020021

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.